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A B S T R A C T
Objectives: The aim of this study was to assess the indirect effect of paediatric 13-valent pneumococcal
conjugate vaccine (PCV13) vaccination on people 65 years of age with invasive pneumococcal disease
(IPD) in Catalonia and to determine factors predictive of mortality.
Methods: During 2014–2016, 1285 IPD cases were reported to the Public Health Agency of Catalonia. The
indirect effect of paediatric PCV13 vaccination was calculated by comparing the incidence rate (IR) in
2016 (PCV13 year) with that in 2009 (pre-PCV13). Predictors of mortality were determined using
multivariate logistic regression.
Results: Comparing 2016 and 2009, IPD decreased by 19% (IR 40.1 and 32.5 per 100 000 person-years,
respectively). PCV13 serotypes decreased by 57% (IR 23.7 and 10.1), while non-PCV13 serotypes increased
by 36% (IR 16.4 and 22.4). During 2014–2016, the mortality rate was 17.5%, and mortality was associated
with age 85 years (adjusted odds ratio (aOR) 2.91, 95% confidence interval (CI) 1.89, 4.48), meningitis
(aOR 2.29, 95% CI 1.25, 4.19), non-focal bacteraemia (aOR 3.73, 95% CI 2.00, 6.94), and 1 high-risk
condition (aOR 1.89, 95% CI 1.08, 3.32). PPV23non13 serotypes were associated with lower mortality than
PCV13 serotypes (aOR 0.54, 95% CI 0.34, 0.86).
Conclusions: The incidence of IPD in people 65 years of age decreased after the introduction of paediatric
PCV13, and this was due to a reduction in PCV13 serotypes, although an increase in non-PCV13 serotypes
was observed. Mortality was associated with age, meningitis, non-focal bacteraemia, 1 high-risk
condition, and PCV13 serotypes.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Streptococcus pneumoniae is a leading cause of severe disease
worldwide, causing around one million deaths annually that affect
mainly children and older people (Liu et al., 2016). Immunization of
children with pneumococcal conjugate vaccines (PCV) has reduced
the incidence of invasive pneumococcal disease (IPD) due to PCV
serotypes in children, as well as in unvaccinated age groups, due to
herd protection. However, other non-vaccine serotypes have
emerged in children and adults (Whitney et al., 2003; Pilishvili
et al., 2010; Pelton et al., 2004).
The 23-valent pneumococcal polysaccharide vaccine (PPV23)
has been indicated for people aged 65 years and those aged <65
years at increased risk of IPD (Pebody et al., 2005) since 1983. In
2012, the Advisory Committee on Immunization Practices recom-
mended one dose of PCV13 vaccine followed by one dose of PPV23
at least 8 weeks later in people aged 19 years with high-risk
conditions (Centers for Disease Control and Prevention (CDC),
2012).
In Catalonia, Spain, PPV23 was introduced for persons aged
>2 years with a high-risk condition and older adults in 1999
(Generalitat de Catalunya, 2014). The 13-valent pneumococcal
conjugate vaccine (PCV13) was included in the routine
vaccination schedule for children in 2016 and recommended
for persons with high-risk conditions. Prior to this date,
children aged <5 years with risk factors were vaccinated with
PCV13 free of charge, and in addition, other children were
vaccinated with available PCVs according to the recommenda-
tion of their paediatrician (Generalitat de Catalunya, Departa-
ment de Salut, 2018).
Factors related to the host, such as age and underlying diseases
(Hausdorff et al., 2000; Feikin et al., 2000; Niederman et al., 2001;
Moroney et al., 2001; Yu et al., 2003), and factors related to the
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The objectives of this study were to assess the indirect effect of
PCV13 vaccination in children on people 65 years of age in
Catalonia and to determine the factors predictive of the IPD case
fatality rate in this age group.
Methods
Study population
The Catalan population 65 years of age was 1,217,519 in 2009
and increased to 1,379,277 by 2016 (Institut d’Estadística de
Catalunya, 2019).
Case definition
An IPD case was defined as a patient aged 65 years with clinical
symptoms of infection (e.g., pneumonia, meningitis) together with S.
pneumoniae isolation by culture or S. pneumoniae DNA detection by
PCR or antigen detection in a normally sterile site (e.g., blood,
cerebrospinal fluid, pleural fluid, joint fluid, peritoneal fluid, or lung
tissue). Only one IPD episode per patient was included, unless
clinical sample collection dates were separated by >30 days or the
serotypes identified differed.
Vaccination policy and vaccine uptake
The estimated 7-valent PCV (PCV7) coverage in Catalonia was
58.7% in children aged <5 years (2007–2009) (Ciruela et al., 2013a).
PCV13 and 10-valent PCV coverage in children aged <2 years was
64% and 4%, respectively (2012–2013) (Savulescu et al., 2017).
Estimated PPV23 coverage was around 50% in older people in
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Table 1
Changes in demographic, clinical, and microbiological characteristics of patients
65 years of age with IPD before and after the introduction of PCV13; Catalonia,
2009 and 2016.
2009 (n = 488) 2016 (n = 448) p-Value
n (%) n (%)
Age group (years)
65–74 168 (34.4) 168 (37.5) 0.340
75–84 202 (41.4) 144 (32.1) 0.004
85 118 (24.2) 136 (30.4) 0.039
Sex
Male 264 (54.1) 252 (56.3) 0.512
Clinical presentation
All pneumonia 409 (83.8) 369 (82.4) 0.600
Empyema 30 (6.1) 18 (4.0) 0.181
Non-focal bacteraemia 37 (7.6) 28 (6.3) 0.443
Meningitis 26 (5.3) 38 (8.5) 0.069
Other formsa 16 (3.3) 13 (2.9) 0.851
Hospitalization
(*n = 357; **n = 428)
Yes 350 (98.0) 416 (97.2) 0.492
Length of hospital stay
(*n = 331; **n = 410)
15 days 85 (25.6) 287 (24.4) 0.189
ICU admission
(*n = 225; **n = 414)
Yes 84 (25.4) 87 (21.2) 1
Underlying diseases
(*n = 302; **n = 414)
At risk 157 (52) 213 (49.6) 0.548
Chronic cardiovascular disease 58 (19.2) 57 (13.3) 0.039
Chronic lung disease 12 (4.0) 18 (4.2) 1
Diabetes 19 (6.3) 34 (7.9) 0.470
Cirrhosis 4 (1.3) 5 (1.2) 1
Alcoholism 1 (0.3) 1 (0.2) 1
Smoking 3 (1.0) 1 (0.2) 0.388
CSF leakage 0 (0.0) 2 (0.5) 0.639
>1 at-risk condition 60 (19.9) 95 (22.1) 0.520
High risk 102 (33.8) 159 (37) 0.389
Chronic renal disease 4 (1.3) 19 (4.4) 0.018
Immunodeficiency 34 (11.3) 25 (5.8) 0.009
Asplenia 0 (0.0) 0 (0.0) 1
Transplant 1 (0.3) 0 (0.0) 0.860
>1 high-risk condition 63 (20.9) 115 (26.8) 0.067
No condition 43 (14.2) 57 (13.3) 0.744
Influenza vaccination
(*n = 445; **n = 439)
Yes 199 (44.7) 202 (46.0) 0.736
PPV23 vaccination
Vaccinated 184 (41.3) 270 (61.5) <0.001
(*n = 445; **n = 439)
PPV23  5 years 112 (60.9) 216 (80.0) <0.001
PPV23 < 5 years 72 (39.1) 54 (20.0) <0.001
Non-vaccinated 261 (58.7) 169 (38.5) <0.001
Penicillin
(*n = 420; **n = 372)
Non-susceptible 104 (24.8) 97 (26.1) 0.683
Cefotaxime
(*n = 420; **n = 372)
Non-susceptible 47 (11.2) 51 (13.7) 0.334
Abbreviations: IPD, invasive pneumococcal disease; PCV13, 13-valent pneumococ-
cal conjugate vaccine; CSF leakage, cerebral spinal fluid leakage; ICU, intensive care
unit; PPV23, 23-valent pneumococcal polysaccharide vaccine.
a Other forms: abdominal (15 cases), osteoarticular (10 cases), cellulitis (3 cases),
endocarditis (1 case).
* 2009.
** 2016.
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An active and retrospective study of all laboratory-confirmed
IPD cases reported to the Microbiological Reporting System (MRS)
of the Public Health Agency of Catalonia was conducted. The MRS
involves 50 centres, representing over 85% of hospital beds in
public hospitals. All Catalonian reference hospitals were included.
In addition, cases from some private hospitals that send strains to
regional and national reference laboratories were also recovered in
order to study the serotypes (Ciruela et al., 2018).
The variables included were age, sex, clinical form, serotype and
antibiotic susceptibility. Clinical form was stratified into pneumo-
nia, empyema, non-focal bacteraemia, meningitis, and other
clinical forms. Serotyping and antibiotic susceptibility testing
were performed by the Public Health Support Laboratory of
Catalonia (Sant Joan de Déu University Hospital) and the National
Centre for Microbiology – Instituto de Salud Carlos III (Madrid,
Spain) as described previously (Fenoll et al., 1997). Meningeal
breakpoints for penicillin were considered for the epidemiological
analysis (The European Committee on Antimicrobial Susceptibility
Testing, 2015). Isolates with intermediate or high-level resistance
were defined as non-susceptible.
The date of hospitalization, intensive care unit (ICU) admission,
IPD-predisposing comorbidities, vaccination history (PPV23, influ-
enzavaccine in the current season), and mortality (30-day mortality)
were collected from the medical records. Comorbidities were
divided into two mutually-exclusive categories: (1) high risk,
including chronic renal failure, HIV, immunodeficiency (medically
induced or innate), asplenia, haematological or metastatic malig-
nancies, CSF leak, and prior neurosurgery, and (2) at risk, including
diabetes mellitus, congestive heart failure, chronic lung disease,
cirrhosis, smoking, and alcoholism (Centers for Disease Control and
Prevention (CDC), 2012). The presence of 2 comorbidities was
classified as ‘>1 high-risk condition’, if one of them was a high-risk
condition, and as ‘>1 at-risk condition’ otherwise.
The length of hospital stay was classified as <15 days or 15
days. The time since the last PPV23 dose was classified as <5 years
or 5 years. Cases were considered vaccinated with PPV23 or
influenza vaccine when they had received a dose of either vaccine
at least 14 days before symptom onset.
Data analysis
The data analysis was performed by comparison of the year 2009
data(baselineyearpriortomarketingofPCV13)totheyear2016 data,
when PCV13 was included in the paediatric vaccination schedule.
Some data from 2014, 2015, and 2016 were also included when
performing the analysis of pneumococcal serotypes, in order to
increase the sample size. The variables studied were the number of
cases, incidence rates (IR), sex, age group, clinical form, serotype
categories, and antibiotic susceptibility. The age groups considered
were 65–74 years, 75–84 years, and 85 years. Serotypes were
grouped into four categories by vaccine coverage: PCV7 (included
serotypes: 4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13non7 (included
serotypes: 1, 3, 5, 6A, 7F, and 19A), PPV23non13 (included serotypes:
2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F), and nonPPV23
serotypes (serotypes not included in PPV23 and not serotype 6A).
The indirect effect of PCV13 in people 65 years of age was
calculated by comparing the IR in 2016 with the IR in 2009 by serotype
categoryandagegroup.Forcaseswithmissingserotypeinformation, it
was assumed that the serotype distribution was the same as among
cases with the known serotype in the same year and age group.
Changes in the estimated IR were assessed by incidence rate ratios
(IRR) with 95% confidence intervals (CI) and were expressed as the
percentage change in incidence. Proportions were compared using the
Chi-square test or Fisher’s exact test, as appropriate.To determine predictors of the case fatality rate during 2014–2016,
multivariate logistic regression was used. The model included all
variables with a value of p < 0.2 in the univariate regression analyses.
The odds ratios (OR) and 95% CI were calculated.
Two-sided p-values of <0.05 were considered statistically
significant. The analyses were conducted using the IBM SPSS
Statistics version 19.0 (IBM Corp., Armonk, NY, USA) and R 2.13.0
(R Development Core Team 2014).
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Characteristics of IPD in people older than 64 years of age
A total of 488 IPD cases were reported in 2009 compared to 448
cases in 2016 (Table 1). The highest number of cases was in the 75–
84 years age group in 2009 (41.4%) and in the 65–74 years age
group in 2016 (37.5%). There was an increase in cases in the 85
years age group (24.2% vs. 30.4%; p = 0.039) and a decrease in the
75–84 years age group (41.4% vs. 32.1%; p = 0.004) in 2016
compared to 2009. The predominant clinical form was pneumonia
(83.8% in 2009, 82.4% in 2016). More than a quarter of patients
were admitted to the ICU in 2009 (25.4%) and 21.2% in 2016. There
was no change between 2009 and 2016 regarding clinical forms,
hospitalization, and ICU admission.
One hundred and fifty-seven cases (52.0%) had 1 at-
riskcomorbidity in 2009 compared to 213 cases (49.6%) in
2016. Furthermore, 102 (33.8%) cases in 2009 compared to 159
(37.0%) cases in 2016 had 1 high-risk comorbidity. There
were no significant differences between these categories in
the years analysed. Only chronic cardiovascular disease (19.2%
vs. 13.3%; p = 0.039) and immunodeficiency (11.3% vs. 5.8%;
p = 0.009) declined in 2016, whereas chronic renal disease
increased (1.3% vs. 4.4%; p = 0.018). IPD cases vaccinated with
PPV23 increased in 2016 (41.3% vs. 61.5%; p < 0.001), although
cases vaccinated within the previous 5 years declined (39.1% vs.
20.0%; p < 0.001).
Antibiotic susceptibility testing was performed on 420 (86.1%)
isolates in 2009 and 372 (83.0%) isolates in 2016; of these, 24.8%
and 26.1% (p = 0.683), respectively, were non-susceptible to
penicillin and 11.2% and 13.7% (p = 0.334), respectively, were
non-susceptible to cefotaxime.Figure 1. Estimated IPD incidence rate by year, age group and vaccine serotypes in pa
Abbreviations: IPD, invasive pneumococcal disease; PCV7 serotypes, serotypes include
serotypes included in 13-valent pneumococcal conjugate vaccine; PPV23non13, additio
serotypes not included in 23-valent pneumococcal polysaccharide vaccine and not 6A.Indirect effect of PCV13 on IPD in people older than 64 years of age
During 2014–2016, the IPD IR was between 29.0 and 33.0 per
100 000 person-years in 2014 and 2015, respectively (Figure 1).
The highest incidence was in the age group 85 years (52.0 in 2014
and 63.2 in 2016). The serotype was available in 1114 (86.7%) cases.
The estimated serotypes included in PCV13, PPV23non13, and non-
vaccine serotypes represented 34.8%, 35.0%, and 30.2% of cases,
respectively. The most frequent serotypes were 3 (11.6%), 8 (8.3%),
14 (7.3%), 12F (6.8%), 22F (5.2%), and 19A (4.9%), which are included
in PCV13 and PPV23 (Figure 2A, B).
Changes in estimated IR and serotype groups between 2009 and
2016 are shown in Table 2. Global IPD IR decreased by 19% in 2016
(40.1 and 32.5 per 100 000 person-years, respectively; IRR 0.81,
95% CI 0.71, 0.92). The incidence of serotypes included in PCV13
showed a decrease of 57% in 2016, mainly due to the PCV13non7
serotypes (70%). However, non-PCV13 serotypes increased by 36%,
especially due to PPV23non13 serotypes (80%).
PCV13 serotypes decreased in all age groups, between 51% in
people aged 85 years and 60% in those aged 75–84 years. Non-
PCV13 serotypes increased in all age groups, but the difference was
statistically significant only in the 65–74 years age group,
increasing by 62% (10.8 and 17.5 per 100 000 person-years in
2009 and 2016, respectively; IRR 1.62, 95% CI 1.19, 2.23).
Predictors of the case fatality rate
During 2014–2016, there were 219/1253 fatal cases (17.5%), which
increased with age from 12.2% in people aged 65–74 years to 25.7% in
those aged 85 years (Table 3). The case fatality rate was higher in
people with comorbidities (at-risk 15.6% and high-risk 21.2%)
than in healthy people (13.9%). In the univariate analysis, older age,tients aged 65 years. Catalonia, 2014–2016.
d in 7-valent pneumococcal conjugate vaccine; PCV13non7 serotypes, additional
nal serotypes included in 23-valent pneumococcal conjugate vaccine; Non-PPV23,
Figure 2. (A) Estimated IPD incidence rate caused by PCV13 serotypes in patients aged 65 years. Catalonia, 2014–2016. (B) Estimated IPD incidence rate caused by
PPV23non-PCV13 serotypes and non-PPV23 serotypes in patients aged 65 years. Catalonia, 2014–2016.
Abbreviations: IPD, invasive pneumococcal disease; PCV7 serotypes, serotypes included in 7-valent pneumococcal conjugate vaccine; PCV13non7 serotypes, additional
serotypes included in 13-valent pneumococcal conjugate vaccine; PPV23non13, additional serotypes included in 23-valent pneumococcal conjugate vaccine.
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bacteraemia, and other clinical forms were associated with greater
mortality. IPD due to PPV23non13 serotypes had a lower case fatality
rate than PCV13 serotypes, whereas non-susceptibility to penicillin
and cefotaxime were risk factors for mortality.Age, clinical form, high-risk condition, serotype by vaccine type,
and antibiotic susceptibility to penicillin and cefotaxime had a
p-value of <0.2 in the univariate analysis and were included in the
final regression model. The case fatality rate showed a significant
difference in people aged 85 years compared to those aged 65–74
Table 2
Changes in estimated incidence rate of IPD by vaccine serotypes in patients 65 years of age before and after the introduction of PCV13 and estimates of the indirect effect;
Catalonia, 2009 and 2016.
Age and serotype categories 2009 2016 IRR (95% CI) Indirect effect estimatesa %
(95% CI)
Estimated (raw) cases IR Estimated (raw) cases IR
65 years 488 40.1 448 32.5 0.81 (0.71, 0.92) 19 (8, 29)
PCV13 288 (246) 23.7 139 (116) 10.1 0.43 (0.35, 0.52) 57 (48, 65)
PCV7 79 (70) 6.5 67 (56) 4.9 0.75 (0.53, 1.05) 25 (5, 47)
PCV13non7 209 (176) 17.2 72 (60) 5.2 0.30 (0.23, 0.40) 70 (60, 77)
Non-PCV13 200 (178) 16.4 309 (257) 22.4 1.36 (1.14, 1.64) 36 (64, 14)
PPV23non13 87 (78) 7.1 177 (145) 12.8 1.8 (1.38, 2.35) 80 (135, 38)
Non-PPV23 113 (100) 9.3 132 (112) 9.6 1.03 (0.80, 1.34) 3 (34, 20)
65–74 years 168 28.4 168 24.3 0.86 (0.69, 1.07) 14 (7, 31)
PCV13 104 (92) 17.6 47 (39) 6.8 0.39 (0.27, 0.55) 61 (45, 73)
PCV7 33 (29) 5.6 20 (16) 2.9 0.52 (0.28, 0.93) 48 (7, 72)
PCV13non7 71 (63) 12.0 27 (23) 3.9 0.33 (0.20, 0.51) 67 (49, 80)
Non-PCV13 64 (57) 10.8 121 (104) 17.5 1.62 (1.19, 2.23) 62 (123, 19)
PPV23non13 29 (25) 4.9 84 (71) 12.2 2.48 (1.61, 3.92) 148 (292, 61)
Non-PPV23 35 (32) 5.9 37 (33) 5.4 0.91 (0.55, 1.48) 9 (48, 45)
75–84 years 202 43.4 144 30.7 0.71 (0.57, 0.88) 29 (12, 43)
PCV13 118 (97) 25.4 48 (39) 10.2 0.4 (0.28, 0.57) 60 (43, 72)
PCV7 26 (23) 5.6 21 (17) 4.5 0.80 (0.43, 1.48) 20 (42, 55)
PCV13non7 92 (74) 19.8 27 (22) 5.8 0.29 (0.18, 0.45) 71 (55, 81)
Non-PCV13 84 (72) 18.1 96 (73) 20.5 1.13 (0.84, 1.54) 13 (54, 16)
PPV23non13 38 (33) 8.2 51 (38) 10.9 1.33 (0.86, 2.08) 33 (108, 14)
Non-PPV23 46 (39) 9.9 45 (35) 9.6 0.97 (0.63, 1.50) 3 (50, 37)
85 years 118 73 136 61.6 0.84 (0.65, 1.09) 16 (9, 35)
PCV13 66 (57) 40.8 44 (38) 19.9 0.49 (0.33, 0.73) 51 (27, 67)
PCV7 20 (18) 12.4 26 (23) 11.8 0.95 (0.51, 1.80) 5 (80, 49)
PCV13non7 46 (39) 28.5 18 (15) 8.2 0.29 (0.16, 0.50) 71 (50, 84)
Non-PCV13 52 (49) 32.2 92 (80) 41.7 1.30 (0.91, 1.86) 30 (86, 9)
PPV23non13 20 (20) 12.4 42 (36) 19.0 1.54 (0.88, 2.77) 54 (177, 12)
Non-PPV23 32 (29) 19.8 50 (44) 22.7 1.14 (0.72, 1.84) 14 (84, 28)
Abbreviations: IPD, invasive pneumococcal disease; IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; PCV13, serotypes included in the 13-valent
pneumococcal conjugate vaccine; PCV7, serotypes included in the 7-valent pneumococcal conjugate vaccine; PCV13non7, additional serotypes included in the 13-valent
pneumococcal conjugate vaccine; Non-PCV13, serotypes not included in the 13-valent pneumococcal conjugate vaccine; PPV23non13, additional serotypes included in the
23-valent pneumococcal conjugate vaccine; Non-PPV23, serotypes not included in the 23-valent pneumococcal polysaccharide vaccine and not 6A.
a Note: A negative indirect effect indicates an increased incidence, while a positive effect indicates a decrease effect.
Table 3
Predictors of death in IPD patients 65 years of age; Catalonia, 2014–2016.
Death
Yes (n = 219) No (n = 1,034)
n (%) n (%) OR (95% CI) p-Value aOR* (95% CI) p-Value
Age group (years) 65-74 (n=467) 57 (12.2) 410 (87.8) 1 1
75-84 (n=440) 73 (16.6) 367 (83.4) 1.43 (0.98,2.08) 0.060 1.50 (0.97,2.32) 0.068
85 (n=346) 89 (25.7) 257 (74.3) 2.49 (1.73,3.60) <0.001 2.91 (1.89,4.48) <0.001
Sex Female (n=556) 103 (18.5) 453 (81.5) 1
Male (n=697) 116 (16.6) 581 (83.4) 1.14 (0.85,1.53) 0.384
Clinical presentation All pneumonia (n=1,031) 156 (15.1) 875 (84.9) 1 1
Meningitis (n=99) 24 (24.2) 75 (75.8) 1.80 (1.10,2.93) 0.019 2.29 (1.25,4.19) 0.007
Non-focal bacteraemia (n=68) 24 (35.3) 44 (64.7) 3.06 (1.81,5.18) <0.001 3.73 (2.00,6.94) <0.001
Other forms (n=55) 15 (27.3) 40 (72.7) 2.00 (1.13,3.90) 0.018 1.60 (0.76,3.41) 0.219
Comorbidities No risk condition (n=180) 25 (13.9) 155 (86.1) 1 1
1 at-risk condition (n=584) 91 (15.6) 493 (84.4) 1.14 (0.71,1.85) 0.580 1.21 (0.69,2.10) 0.508
1 high-risk condition (n=468) 99 (21.2) 369 (78.8) 1.66 (1.03,2.68) 0.037 1.89 (1.08,3.32) 0.027
Serotypes categories PCV13 (n=378) 76 (20.1) 302 (79.9) 1 1
PPV23non13 (n=367) 38 (10.4) 329 (89.6) 0.46 (0.30,0.70) <0.001 0.54 (0.34,0.86) 0.010
Non-PPV23 (n=332) 71 (21.4) 261 (78.6) 1.08 (0.75,1.56) 0.675 1.07 (0.69,1.65) 0.768
Penicillin Susceptible (n=778) 120 (15.4) 658 (84.6) 1 1
Non-susceptible (n=284) 61a (21.5) 223b (78.5) 1.50 (1.06,2.12) 0.021 0.91 (0.56,1.48) 0.907
Cefotaxime Susceptible (n=935) 151 (16.1) 784 (83.9) 1 1
Non-susceptible (n=127) 30c (23.6) 97d (76.4) 1.61 (1.03,2.51) 0.037 1.38 (0.70,2.69) 0.350
Influenza vaccination Not vaccinated (n=652) 114 (17.5) 538 (82.5) 1
Vaccinated (n=600) 104 (17.3) 496 (82.7) 0.99 (0.74,1.33) 0.944
Abbreviations: IPD, invasive pneumococcal disease; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; PCV13, serotypes included in the 13-valent
pneumococcal conjugate vaccine; PPV23non13, additional serotypes included in the 23-valent pneumococcal conjugate vaccine; Non-PPV23, serotypes not included in the
23-valent pneumococcal polysaccharide vaccine and not 6A.
* The model included all variables with a value of p < 0.20 in the univariate regression analysis.
a Nine strains were resistant.
b Thirty-one strains were resistant.
c One strain was resistant.
d Two strains were resistant.
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Figure 3. Burden of mortality by serotype distribution in patients aged 65 years. Catalonia, 2014–2016.
Abbreviations: ST, serotype.
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2.29, 95% CI 1.25, 4.19) and non-focal bacteraemia (adjusted OR
3.73, 95% CI 2.00, 6.94) remained associated with mortality. High-
risk comorbidities were also associated with mortality (adjusted
OR 1.89, 95% CI 1.08, 3.32). PPV23non13 serotypes were associated
with lower mortality compared with PCV13 serotypes (adjusted OR
0.54, 95% CI 0.34, 0.86).
Of the 219 deaths, 186 (84.9%) were serotyped, and the most
frequent serotypes were 3 (17.2%), 14 (9.7%), 6C (6.5%), and 24 F
(5.4%) (Figure 3). Of 1034 survivors, 899 were serotyped (86.9%),
and the most frequent serotypes were 3 (10.5%), 14 (6.8%), and 6C
(3.6%). Significant differences between those who died and those
who survived were found for serotypes 3 (17.2% vs.10.5%; p < 0.05),
8 (3.2% vs. 9.5%; p < 0.05), and 12F (1.6% vs. 7.8%; p < 0.05). In the
126 cases with serotype 3, there were 32 deaths (25.4%).
Discussion
The incidence of IPD decreased slightly in people 65 years of
age after the introduction of PCV13 in children. There was a
decrease in PCV13 serotypes, but an important increase in non-
PCV13 serotypes, especially in PPV23non13 serotypes.
Other countries have reported IPD reduction rates ranging from
16% (Regev-Yochay et al., 2017) to 42% (Cabaj et al., 2016; Chalmers
et al., 2016), and a greater decrease (65%) in PCV13 serotypes
(Regev-Yochay et al., 2017) than those found in the present study. A
multicentre European study reported a lower decline in IPD
incidence (9%) than in the present study, with large reductions in
PCV13 serotypes and an increase in non-PCV13 serotypes (63%) in
2011–2015 compared with 2009 (Hanquet et al., 2018).
In the present study, the most frequent serotype in adults was
serotype 3. This serotype represented one of the most frequent
serotypes in other age groups since PCV13 was marketed in
Catalonia (Ciruela et al., 2018). The lack of PCV13 effectivenessagainst serotype 3 in children may be the main reason why there
was no reduction in its incidence (Domínguez et al., 2017). Other
serotypes with high incidences were 8, 14, 12 F, and 22 F (all
PPV23 serotypes, except for serotype 14, which is also included in
PCV13).
No differences were found in clinical form, ICU admission, and
most of the comorbidities between 2009 and 2016, although cases
with chronic cardiovascular disease and immunodeficiency de-
creased and cases with chronic renal disease increased. Sixty-one
percent of IPD patients were vaccinated with PPV23, although the
majority of them had been vaccinated 5 years before. It could be
necessary to improve vaccinationwith PPV23 inolderpeople, mainly
those with risk factors for IPD. PPV23 effectiveness against IPD
remains unclear (Hanquet et al., 2018; Marrie et al., 2011; Jansen
et al., 2009), but it is recommended in persons at risk of IPD and older
people (Generalitat de Catalunya, Departament de Salut, 2018).
Studies on the effectiveness of PPV23 focusing on specific serotypes
and the time of vaccination should be considered. The progressive
decline in PCV13 serotypes and the gradual increase in PPV23non13
serotypes suggest that the potential benefits of PCV13 vaccination in
adults should be regarded with caution.
During 2014–2016, mortality due to IPD was 17.5%, which is lower
than observed in other countries (24–30%) (Harboe et al., 2009; Grau
et al., 2016; van Hoek et al., 2012). The difference in mortality may be
due, in part, to the characteristics of the population, the type of
analysis, and differing serotype distributions.
The study results showed that older age, meningitis or non-
focal bacteraemia, high-risk conditions, and IPD caused by PCV13
serotypes were predictive factors of mortality after adjustment for
possible confounding factors.
Old age is an independent risk factor for mortality, as described in
other studies (Regev-Yochay et al., 2017; Kim et al., 2018; Marrie et al.,
2011). This is probably due to reduced immune function (Jansen et al.,
2009) and an increase in comorbidities (Yu et al., 2003).
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than in healthy people, but only high-risk comorbidities were
associated with mortality in the multivariate analysis. Other studies
have reported an association between at-risk or high-risk conditions
and mortality (Regev-Yochay et al., 2017; Grau et al., 2016),
suggesting that the risk condition of the patient plays a decisive
role in the outcome of IPD, and not only the biological characteristics
of the microorganism, which is in agreement with the present study
results. In contrast, other authors (Kim et al., 2018) have found no
association with either chronic medical conditions or immunocom-
promised conditions after the introduction of PCV13 in children. The
difference is probably due to the statistical analysis or the
characteristics of the populations studied.
The severity of clinical disease was associated with a high risk of
mortality. Meningitis and non-focal bacteraemia were associated
with mortality. Other authors (Kim et al., 2018) who included
referral hospitals found an association with pneumonia, in contrast
to our study. These differences may be explained by the fact that
85% of the reports in the present study corresponded to acute
hospitals (including secondary and tertiary hospitals).
PCV13 serotypes were independently associated with a higher
case fatality rate compared with PPV23non13 serotypes. The most
frequent serotypes causing disease in the patients who died were
3, 14, 6C, and 24F, but only serotype 3 was associated with greater
mortality, in accordance with other studies (Harboe et al., 2009).
Other authors (van Hoek et al., 2012) have found serotypes 19F, 31,
and 3 to have the greatest mortality, with similar percentages (41%,
40%, and 39%, respectively). Serotype 3 has been associated with
serious disease like empyema (Ciruela et al., 2013b), which could
explain, in part, the association with mortality.
This study has some limitations. First, there were some missing
clinical data for 2009, the baseline year. However, the analysis of
mortality predictors was performed using data from 2014–2016
with higher quality of information. Second, serotype information
was missing in 14% of the cases; this limitation was addressed
using estimates to calculate the indirect effect of PCV13 in adults.
A strength of this study is the robust data recorded by the MRS,
which included more than 85% of acute hospital beds. Another
strength is that Catalonia has participated in the European
multicentre SpIDnet project (https://sites.google.com/a/epicon-
cept.fr/ipd-surveillance/home-2) and this has substantially im-
proved the IPD surveillance in our area.
In summary, the incidence of IPD has decreased slightly in people
aged 65 years due to the impact of childhood PCV13 vaccination
although an increase of non-PCV13 serotypes was detected. The case
fatality rate was associated with age, meningitis or non-focal
bacteraemia, high-risk conditions, and PCV13 serotypes. It is
expected that improved PCV13 vaccination coverage in children
and an effective PPV23 vaccination strategy in older adults will
decrease the incidence and severity of IPD in this age group.
Ongoing surveillance of all microbiological and clinical data is
essential to evaluate the preventive measures available.
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